Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS COV2) caused Coronavirus disease 2019 (COVID-19), which was first recorded in Wuhan, China in December 2019 [1]. COVID-19 is primarily a respiratory infection, but it can also affect multiple organ systems including cardiac, neurological, gastrointestinal and renal systems [2]. Viremia and cytokine storm are common in COVID-19 especially in immune-compromised patients, and that may activate the coagulation cascade which causes thrombotic complications and coagulopathies including cardiac thrombosis and disseminated intravascular coagulopathy [3].
D-dimer is a fibrin degradation product, which is used as a biomarker for thrombotic disorders. It is considered normal with values less than 0.5 μg/mL, and the level of D-dimer rises in severe community-acquired pneumonia, it is also used as an initial screening test to diagnose patients who have signs, or symptoms suggestive of venous thromboembolism [4]. D-dimer is detectable in patients with deep venous thrombosis (DVT), as it is a marker of endogenous fibrinolysis. Following the outbreak of the COVID-19 pandemic, D-dimer has been identified as a potential indicator for its prognosis in COVID-19 patients. [5].